Get the Stockscreener App
2.87
1.06%
0.03
After Hours:
2.86
-0.01
-0.35%
OncoCyte Corporation stock is traded at $2.87, with a volume of 62,571.
It is up +1.06% in the last 24 hours and down -2.71% over the past month.
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
See More
Previous Close:
$2.84
Open:
$2.87
24h Volume:
62,571
Relative Volume:
0.82
Market Cap:
$86.51M
Revenue:
$709.00K
Net Income/Loss:
$-43.14M
P/E Ratio:
-0.6322
EPS:
-4.54
Net Cash Flow:
$-20.35M
1W Performance:
-5.12%
1M Performance:
-2.71%
6M Performance:
+0.35%
1Y Performance:
+0.00%
1-Day Range:
$2.8107
$2.96
1-Week Range:
$2.7801
$3.32
52-Week Range:
$1.922
$4.75
OncoCyte Corporation Stock (OCX) Company Profile
Name
OncoCyte Corporation
Sector
Industry
Phone
510-775-0515
Address
1010 Atlantic Avenue, Suite 102, Alameda, CA
Compare OCX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCX
OncoCyte Corporation
|
2.87 | 86.51M | 709.00K | -43.14M | -20.35M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
OncoCyte Corporation Stock (OCX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-28-25 | Initiated | Lake Street | Buy |
| May-24-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Mar-14-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Mar-17-21 | Resumed | Needham | Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-30-20 | Initiated | BTIG Research | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-30-20 | Reiterated | The Benchmark Company | Speculative Buy |
| Jul-01-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-30-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-02-20 | Initiated | Needham | Buy |
| Feb-13-19 | Initiated | Piper Jaffray | Overweight |
| Jan-29-19 | Upgrade | Janney | Neutral → Buy |
| Dec-19-18 | Resumed | Lake Street | Buy |
View All
OncoCyte Corporation Stock (OCX) Latest News
Oncocyte to Release First Quarter 2025 Results on May 12, 2025 - The Manila Times
Best Momentum Stocks to Buy for May 6th - The Globe and Mail
Geode Capital Management LLC Has $326,000 Stock Position in OncoCyte Co. (NASDAQ:OCX) - Defense World
Oncocyte Provides Positive Update on Clinical Trial Progress | O - GuruFocus
Why Tesla Stock Hit the Brakes Today - The Globe and Mail
AP PHOTOS: US stocks sink after a weak report on the economy - The Globe and Mail
Oncocyte (OCX) Advances Towards Crucial Clinical Trial for Trans - GuruFocus
Oncocyte advances toward clinical trial for transplant test By Investing.com - Investing.com India
Oncocyte advances toward clinical trial for transplant test - Investing.com Australia
Oncocyte Provides Positive Update on Clinical Trial Progress - The Manila Times
Oncocyte Provides Positive Update on Clinical Trial Progress | OCX Stock News - GuruFocus
Oncocyte Provides Positive Update On Clinical Trial ProgresS - marketscreener.com
Leading US Transplant Centers Back Oncocyte's Revolutionary Rejection Test Clinical Trial - Stock Titan
OncoCyte (NASDAQ:OCX) Trading Down 3.1% – Here’s What Happened - Defense World
Oncocyte study links blood test to kidney rejection markers - Investing.com
Economic Uncertainty Weighs on PayPal - The Globe and Mail
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Val - GuruFocus
Oncocyte (OCX) Unveils Promising Data on Transplant Rejection Te - GuruFocus
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity | OCX Stock News - GuruFocus
Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity - The Manila Times
Groundbreaking Study: Oncocyte's Transplant Test Shows Unprecedented 13-Year Effectiveness in Rejection Detection - Stock Titan
Trane Technologies (TT) Reports Earnings Tomorrow: What To Expect - The Globe and Mail
Service International (SCI) Reports Q1: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
Public market insider selling at Metro (MRU) - The Globe and Mail
Oncocyte appoints new independent accounting firm - Investing.com
Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer - The Globe and Mail
BioTime Provides Business Update Including Information on AgeX, OncoCyte and Asterias - MarketScreener
OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
OncoCyte (NASDAQ:OCX) Coverage Initiated by Analysts at StockNews.com - Defense World
OncoCyte Co. (NASDAQ:OCX) Sees Large Increase in Short Interest - Defense World
Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference - TradingView
Oncocyte Unveils Game-Changing Transplant Diagnostic Technology at Major Healthcare Conference - Stock Titan
Analysts’ Recent Ratings Updates for OncoCyte (OCX) - Defense World
Oncocyte Files Secondary Stock Shelf - MarketScreener
OncoCyte (NASDAQ:OCX) Now Covered by Lake Street Capital - Armenian Reporter
Lake Street Capital Initiates Coverage on OncoCyte (NASDAQ:OCX) - Defense World
Lake Street starts OncoCyte coverage with Buy, $5 target By Investing.com - Investing.com Canada
OncoCyte a new buy at Lake Street on transplant rejection testing - MSN
OncoCyte’s Strategic Positioning and Growth Potential in Transplant Rejection Testing - TipRanks
OncoCyte initiated with a Buy at Lake Street - TipRanks
Lake Street Initiates Coverage on OncoCyte (OCX) with Buy Rating - GuruFocus
Lake Street starts OncoCyte coverage with Buy, $5 target - Investing.com India
Why Bausch + Lomb (BLCO) Shares Are Plunging Today - The Globe and Mail
OncoCyte (NASDAQ:OCX) Given Buy Rating at Needham & Company LLC - Defense World
OncoCyte (NASDAQ:OCX) Receives “Equal Weight” Rating from Stephens - Defense World
OncoCyte Corp’s Positive Earnings Call Highlights Growth - TipRanks
OncoCyte Corp (OCX) Q4 2024 Earnings Call Highlights: Strategic Partnerships and Regulatory ... - Yahoo
Earnings call transcript: OncoCyte’s Q4 2024 revenue grows, strategic advances - Investing.com Australia
Needham maintains Buy on OncoCyte, steady $4.25 target - Investing.com India
OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Call Transcript - Insider Monkey
OncoCyte Corporation Stock (OCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):